Drug Trial Radar · NCT00235391
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Last checked: Nov 20, 2026Latest source record: Jun 7, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,683
Actual
Start
Oct 2005
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 10, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.
Conditions
- Thalassemia
- Sickle Cell Disease
- Diamond Blackfan Anemia
- Myelofibrosis
Interventions
DeferasiroxDrug
125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse EventsTime frame: Baseline to end of study (Median exposure time to drug was approximately 30 weeks; Maximum exposure was 104 weeks)
Locations
141 sites in 12 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital, UAMS College of Medicine
Little Rock, Arkansas
Alta Bates Comprehensive Cancer Center
Berkeley, California
Children's Hospital of Orange County
Orange, California
Children's Hospital and Health Center of San Diego
San Diego, California
Stanford University
Stanford, California
Alfred I. Dupong Hospital for Children
Wilmington, Delaware
Osler Medical, Inc.
Melbourne, Florida
Hematalogy Oncology Associates
Pensacola, Florida
Tampa Children's Hospital at St. Joseph's Hospital
Tampa, Florida
James A. Haley Veterans Hospital
Tampa, Florida
Backus Children's Hospital, Memorial Health University Medical Center
Savannah, Georgia
Hematalogy Oncology Clinic
Baton Rouge, Louisiana
Borgess Hospital
Kalamazoo, Michigan
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
Children's Mercy Hospital
Kansas City, Missouri
The Cancer Institute of New Jersey
New Brunswick, New Jersey
Schneider Children's Hospital
New Hyde Park, New York
PCTI
Columbus, Ohio
The Children's Medical Center of Dayton
Dayton, Ohio
Oregon Health & Science University
Portland, Oregon
Hershey Medical Center
Hershey, Pennsylvania
Children's Hospitals of Pittsburgh
Pittsburgh, Pennsylvania
Texas Children's Hospital
Houston, Texas
Children's Hospital of the Kings Daughters
Norfolk, Virginia
VCU Pediatric Hematology/Oncology
Richmond, Virginia
University of Washington Seattle Cancer Care Alliance
Seattle, Washington
Ziekenhuisnetwerk Antwerpen-AZ Middelheim
Antwerp, Belgium
Centre Hospitalier Notre Dame et Reine
Charleroi, Belgium
CHR de la Citadelle
Liège, Belgium
Centre Hospitalier Chretien-Clinique Saint-Joseph
Montegnée, Belgium
University of Alberta
Edmonton, Canada
CHUM-Hopital-Notre-Dame
Montreal, Canada
MUHC- Montreal Children's Hospital
Montreal, Canada
MUHC- Royal Victoria Hospital
Montreal, Canada
Hopital de l'Enfant-Jesus
Québec, Canada
The Hospital for Sick Children,
Toronto, Canada
Toronto General Hospital-Hemoglobinopathy
Toronto, Canada
Burrard Medical Building
Vancouver, Canada
The Ottawa Hospital-General Campus
Ottawa, Ontario, Canada
Showing 40 of 141 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.